



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 **Virtual Congress**



Name	Palak Trivedi
Affiliation	Centre for Liver and Gastrointestinal Research; University of Birmingham
Country	United Kingdom
Major Field	Cholestatic and Immune-Mediated Liver Disease

Educational Background

2002: BSc (hons) in Medical Genetics; St. George's Hospital Medical School, London (UK)
2005: MBBS; St. George's Hospital Medical School, London (UK)
2008: Member of the Royal College of Physicians (MRCP) of London (UK)
2016: PhD in Liver Immunology; University of Birmingham (UK)
2016: MRCP Gastroenterology

Professional Experience

Dr. Trivedi is an Associate Professor at the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC) in the UK. Dr. Trivedi has devoted his clinical and research career to studying chronic cholestatic liver disease, specifically primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). He completed his PhD in Liver Immunology in 2015; during which time his work on risk stratification in rare disease was ranked the top scoring clinical abstract at the EASL International Liver Congress. Dr. Trivedi went on to receive the investigator of the year award in 2017, was recipient of the Andy Burroughs' prize for best Hepatology research at the British Association for Study of the Liver (BASL), and won the Elwyn Elias prize for research into PSC and liver transplantation the same year.

Dr. Trivedi is Chief Investigator for the UK-PSC consortium and was elected chair of the British Association for Study of the Liver Special Interest Group (BASL SIG) for immune-mediated liver disease in 2018. He has >75 articles on PubMed, 48 in the last five years alone; with 38 as original articles, 20 as invited reviews or editorials, and 40 as first or lead author. He has generated >£2.4 million through independent grant funding, with the overarching themes of research in the role of gut-liver immunity in liver disease, modelling the natural history of rare liver disease, and optimising risk stratification to enhance clinical trial design in chronic cholestatic liver disease.

Other Experience and Professional Memberships

2022: Academic Lead for Industry Engagement and Research; University of Birmingham, UK
2021: Associate Professor in Cholestatic and Immune-Mediated Liver Disease
2020: Clinical Research Director; Business Engagement and Industry Sponsored Research, University of Birmingham, UK
2020: Associate Editor; Alimentary Pharmacology and Therapeutics
2019: British Association for Study of the Liver (BASL) Special Interest Group Chair in Immune-Mediated Liver Disease
2018: Chief Investigator; UK-PSC



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



Main Scientific Publications

>75 publications on PubMed, 40 as first/senior author; h index 26, g index >50

(*Trivedi P.J. as first or senior author*)

1. Emerging Drugs for the Treatment of Primary Sclerosing Cholangitis
Abbas N., Quraishi N. and Trivedi PJ
Curr. Opinion. Pharmacol. 2021; Accepted, in press
2. Epidemiology, natural history and outcomes of primary sclerosing cholangitis: A systematic review of population-based studies
Trivedi PJ, Bowlus C, Yimam K, Razavi H and Estes C.
Clin. Gastroenterol. Hepatol. 2021; Epub, ahead of print
3. Recent Advances in Clinical Practice: Epidemiology of Autoimmune Liver Diseases
Trivedi PJ and Hirschfield GM
Gut 2021; Epub, ahead of print
4. Liver disease in secondary care—‘money or your life’
Trivedi PJ
Aliment. Pharmacol. Ther. 2021; Accepted, in press
5. Home-based Exercise in Patients with Refractory Fatigue Associated with Primary Biliary Cholangitis: A Protocol for the EXerCise Intervention in cholestatic Liver Disease (EXCITED) Feasibility Trial
Freer A., Williams F., Durman S, Hayden J., Armstrong MJ.,* Trivedi PJ.*
BMJ Open Gastroenterology 2021;8(1):e000579
6. Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis.
Trivedi PJ, Muir AJ, Levy C, Bowlus CL, Manns M, Lu X, Crans G, Chung C, Subramanian GM, Myers RP, Goodman Z, Chalasani N, Vierling JM, Guha IN and Hirschfield GM.
Clin Gastroenterol Hepatol. 2021;19(6):1248-1257
7. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age
Trivedi PJ, Crothers H, Mytton J, Bosch S, Iqbal T, Ferguson J and Hirschfield GM
Gastroenterology 2020;159(3):915-928.
8. Risk stratification in primary sclerosing cholangitis: It's time to move on from replicating imperfection and break the glass ceiling.
Trivedi PJ
J. Hepatol. 2019;71(5):867-870
9. Grand round: Autoimmune hepatitis.
Trivedi PJ, Hubscher SG, Heneghan M, Gleeson D, Hirschfield GM.
J. Hepatol. 2019;70(4):773-784.
10. Patterns of Disease Progression and Incidence of Complications in Primary Biliary Cholangitis (PBC)



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



- Janmohamed A. and Trivedi P.J.
Best Practice & Research Clinical Gastroenterology 2018;34-35:71-83
11. The impact of ileal-pouch anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis
Trivedi PJ, Reece J., Laing RW, Slaney E, Cooney R, Gunson B, Kathir S, Pinkney T, Thompson F, Muiesan P, Schlegel A, Hirschfield GM, Iqbal T and Ferguson J.
Alimentary Pharmacology and Therapeutics 2018;48(3):322-332
 12. The Paddington International virtual ChromoendoScopy ScOre (PICaSSO) in ulcerative colitis exhibits very good inter-rater agreement after computerized module training: a multicenter study across academic and community practice
Trivedi PJ, Kiesslich R, Hodson J, Bhala N, Boulton RA, Cooney R, Gui X, Iqbal T, Li KK, Mumtaz S, Pathmakanthan S, Quraishi MN, Sagar VM, Shah A, Sharma N, Siau K, Smith S, Ward S, Widlak MM, Bisschops R, Ghosh S and Iacucci M
Gastrointest Endosc. 2018;88(1):95-106.e2
 13. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, facilitates adhesion of gut-tropic lymphocytes to liver endothelium in a substrate-dependent manner and is predictive of clinical outcome
Trivedi PJ, Tickle J, Vesterhus M., Eddowes P. Bruns T., Parker R., Vainio J., Smith D., Liaskou E., Hirschfield GM, Auvunen K, Salmi M, Hubscher SG, Adams DH and Weston CJ.
Gut 2018;67(6):1135-1145.
 14. Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient Truths.
Armstrong MJ., Mellinger JL and Trivedi PJ.
Am. J. Gastroenterol. 2018;113(10):1437-1439
 15. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise
Trivedi PJ and Adams DH
Journal of Crohn's and Colitis 2018;S641-S652.
 16. Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis.
Trivedi PJ, Scalera I, Schlegel A, Slaney E, Laing R, Hirschfield G, Gunson B, Muiesan P. and Ferguson J.
Journal of Hepatology 2017; 67(5):957-965.
 17. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.
Trivedi PJ,* Weismuller TJ,* Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Beuers U, Gotthardt D, Marschall H-U, Thorburn D, Weersma RK, Fevery J, Mueller T, Corpechot C, Chazouillères O, Schramm C, Lohse A, Lazaridis K, Juran BD, Färkkilä M, Pereira SP, Almer S, Levy C, Mason A, Bowlus CL, Floreani A, Halilbasic E, Trauner M, Yimam KK, Milkiewicz P, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Kirchner GI, Sarrazin C, Zimmer V,³⁵ Fabris L, Invernizzi P, Braun F, Marzioni M, Berg



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



- CP, Chapman RW Strassburg CP, Manns MP, Lindor KD, Karlsen TH, Hirschfield GM, Hansen BE and Boberg KM
Gastroenterology 2017;152(8):1975-1984e8
18. The therapeutic potential of targeting CCL25/CCR9 in colonic inflammatory bowel disease – reading between the lines
Trivedi PJ, Bruns T, Schmidt C
Alimentary Pharmacology and Therapeutics 2016; 44(3):307-8
19. Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity
Trivedi PJ, Bruns T, Ward S, Mai M, Schmidt C, Hirschfield GM, Weston CJ and Adams DH
Journal of Autoimmunity 2016; 68:98-104
20. Gut-liver immunity
Trivedi PJ and Adams DH
Journal of Hepatology 2016; 64(5):1187-9
21. Obeticholic acid for the treatment of primary biliary cirrhosis
Trivedi PJ, Hirschfield GM and Gershwin ME
Expert Review of Clinical Pharmacology 2016; 9(1):13-26
22. Risk Stratification in Autoimmune Cholestatic Liver Disease: Opportunities for Clinicians and Trialists
Trivedi PJ, Corpechot C, Pares A and Hirschfield GM
Hepatology 2016; 63(2):644-59
23. Immunogenetics of PBC and PSC
Trivedi PJ and Hirschfield GM
Clinics in Liver Disease 2016; 20(1):15-31
24. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study
Trivedi PJ, Lammers WJ, van Buuren HR, Parés A, Floreani A, Janssen HL, Invernizzi P, Battezzati PM, Ponsioen CY, Corpechot C, Poupon R, Mayo MJ, Burroughs AK, Nevens F, Mason AL, Kowdley KV, Lleo A, Caballeria L, Lindor KD, Hansen BE and Hirschfield GM; On behalf of the Global PBC Study Group
Gut 2016; 65(2):321-9
25. Serum alkaline phosphatase in multidrug resistance 2 (*Mdr2*^{-/-}) mice is strain-specific
Trivedi PJ, Weston CJ, Webb GJ, Newsome PN, Hirschfield GM and Adams DH
Hepatology 2016; 63(1):346
26. Primary biliary cirrhosis: Renaming primary biliary cirrhosis-clarity or confusion?
Trivedi PJ, Hirschfield GM
Nature Reviews Gastroenterology and Hepatology 2015; 12(12):678-9



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology



April 16-17, 2022 Virtual Congress

27. Author's reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis"
Trivedi PJ, Bruns T, Li KK, Hirschfield GM
Journal of Hepatology 2014; 61(6):1445-6
28. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response
Trivedi PJ, Bruns T, Cheung A, Li KK, Kittler C, Kumagi T, Shah H, Corbett C, Al-Harthy N, Acarsu U, Coltescu C, Tripathi D, Stallmach A, Neuberger J, Janssen HL and Hirschfield GM
Journal of Hepatology 2014; 60(6):1249-58
29. Good Maternal and Fetal Outcomes for Pregnant Women with Primary Biliary Cirrhosis
Trivedi PJ, Kumagi T, Al-Harthy N, Coltescu C, Ward S, Cheung A and Hirschfield GM
Clinical Gastroenterology and Hepatology 2014; 12(7): 1179-1185
30. Frequency and Significance of IgG4 Immunohistochemical Staining in Liver Explants from Patients with Primary Sclerosing Cholangitis
Trivedi PJ, * Fischer S, Ward S, Greig P, Therapondos G and Hirschfield GM
International Journal of Experimental Pathology 2014; 95(3): 209-15
31. Mucosal Immunity in Liver Autoimmunity
Trivedi PJ and Adams DH
Journal of Autoimmunity 2013; 46:97-111
32. Treatment of autoimmune liver disease: current and future therapeutic options
Trivedi PJ and Hirschfield GM
Therapeutic Advances in Chronic Disease 2013; 4(3):119-41
33. Indications, stains and techniques in chromoendoscopy
Trivedi PJ and Braden B
QJM 2013; 106(2):117-31
34. Protein protein everywhere.. but none to keep
Trivedi PJ, * Pavlides M, Gill P, Appleton S, Cullen S and McIntyre A
Gut 2013; 62(2):298,329
35. Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments
Trivedi PJ and Cullen S
Hepatology International 2013; 7 (1): 28-47
36. The hepato-enteric immune system
Trivedi PJ and Adams DH
Clinical Medicine 2012; 12-6-s74
37. Overlap syndromes and autoimmune liver disease
Trivedi PJ and Hirschfield G
Alimentary Pharmacology and Therapeutics 2012; 36(6): 517-33



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



38. Appropriate Patient Selection in the Management of Common Bile Duct Stones
Trivedi PJ, Tse D Al-Bakir I and Da Costa H
ISRN Surgery 2012; 2012: 286365
 39. PSC, AIH and Overlap Syndrome in IBD
Trivedi PJ, Chapman RW
Clinics and Research in Hepatology and Gastroenterology 2012; 36(5):420-36
 40. Altered Bile Acid Pool using IBAT Inhibitors for Constipation: A Potentially Increased Risk of Malignancy
Trivedi PJ, Ward S
American Journal of Gastroenterology 2012; 107(1):140
 41. Recent Advances in Immunotherapy: Mucosal Dendritic Cell-Epithelial Crosstalk
Trivedi PJ
Immunotherapy 2012; 4(1):23-6
 42. Autoimmune Hepatitis, Cirrhosis and Hepatocellular Carcinoma (HCC)
Trivedi PJ and Cullen S
Digestive Diseases and Science 2011; 56(2):276-8
 43. Biloma: An Unusual Complication in a Patient with Pancreatic Cancer
Trivedi PJ, Gupta P, Phillips-Hughes J and Ellis A
World Journal of Gastroenterology 2009; 15 (41): 5218-20
 44. An Unusual Case of Dyspnoea in an Elderly Man
Trivedi PJ, Canavan J, Holloway C, Slater A and Travis S
BMJ 2009; bcr0920092247
- (Trivedi P.J. as co-author)
45. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.
Canadian PBC Consortium; Chinese PBC Consortium; Italian PBC Study Group; Japan-PBC-GWAS Consortium; US PBC Consortium; UK-PBC Consortium.
[Collaborative banner authorship]
J Hepatol. 2021 Sep;75(3):572-581
 46. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
Soret PA, Lam L, Carrat F, Smets L, Berg T, Carbone M, Invernizzi P, Leroy V, Trivedi P, Cazzagon N, Weiler-Normann C, Alric L, Rosa-Hezode I, Heurgué A, Cervoni JP, Dumortier J, Potier P, Roux O, Silvain C, Bureau C, Anty R, Larrey D, Levy C, Pares A, Schramm C, Nevens F, Chazouillères O, Corpechot C.
Aliment Pharmacol Ther. 2021;53(10):1138-1146
 47. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.
Haldar D, Janmohamed A, Plant T, Davidson M, Norman H, Russell E, Serevina O, Chung K, Qamar K, Gunson B, Hansen B, Richter A, Trivedi PJ, Hirschfield GM.



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



- Liver Int.* 2021;41(3):535-544.
48. SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question.
Marjot T, Webb GJ, Barritt AS, Ginès P, Lohse AW, Moon AM, Pose E, Trivedi P, Barnes E.
Lancet Gastroenterol Hepatol. 2021;6(3):156-158.
49. Novel use of normothermic machine perfusion of the liver: a strategy to mitigate unexpected clinical events
Carvalho AP, Mackay SC, Bartlett DC, Dronavalli VB, Thilekertane S, Dassanayake B, Kadam P, Boteon Y, Attard J, Rajoriya N, Trivedi P, Armstrong M, Moore R, Bennett D, Murphy N, Singh H, Mirza DF, Rooney SJ, Ranasinghe AM, Perera TPR
Transplantation 2020;104(9):e281-e282.
50. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool.
Murillo Perez CF, Gulamhusein A, Carbone M, Trivedi PJ, van der Meer AJ, Corpechot C, Battezzati PM, Lammers WJ, Cazzagon N, Floreani A, Parés A, Nevens F, Lleo A, Mayo MJ, Kowdley KV, Ponsioen CY, Dalekos GN, Gatselis NK, Thorburn D, Mason AL, Janssen H, Verhelst X, Bruns T, Lindor KD, Chazouillères O, Invernizzi P, Hansen BE, Hirschfield GM; GLOBAL PBC Study Group.
Eur J Gastroenterol Hepatol. 2020 [Epub; ahead of print]
51. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
Corpechot C, Chazouillères O, Belnou P, Montano-Loza AJ, Mason A, Ebadi M, Eurich D, Chopra S, Jacob D, Schramm C, Sterneck M, Bruns T, Reuken P, Rauchfuss F, Roccarina D, Thorburn D, Gerussi A, Trivedi P, Hirschfield G, McDowell P, Nevens F, Boillot O, Bosch A, Giostra E, Conti F, Poupon R, Parés A, Reig A, Donato MF, Malinverno F, Floreani A, Russo FP, Cazzagon N, Verhelst X, Goet J, Harms M, van Buuren H, Hansen B, Carrat F, Dumortier J; Global PBC Study Group.
J Hepatol. 2020;73(3):559-565.
52. Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: a retrospective cohort study.
Cauldwell M, Mackie FL, Steer PJ, Heneghan MA, Baalman JH, Brennan J, Johnston T, Dockree S, Hedley C, Jarvis S, Khan S, McAuliffe FM, Mackillop L, Penna L, Smith B, Trivedi P, Verma S, Westbrook R, Winfield S, Williamson C.
BJOG 2020 [Epub; Ahead of print]
53. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase
Murillo Perez, Harms M, Lindor KD, van Buuren H, Hirschfield GM, Corpechot C, van der Meer A, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE.



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



Am. J. Gastroenterol. 2020 [Epub; Ahead of print]

54. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, Janneke van der Woude C, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretto LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK; International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy C.
Clin Gastroenterol Hepatol. 2020;18(1):179-187.e6
55. The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis.
Cazzagon N, Lemoine S, El Mouhadi S, Trivedi PJ, Gaouar F, Kemgang A, Ben Belkacem K, Floreani A, Hirschfield G, Chretien Y, Housset C, Motta R, Russo FP, Chazouillères O, Arrivé L, Corpechot C.
Am J Gastroenterol. 2019;114(12):1878-1885
56. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response
Murillo Perez CF, Lammers WJ, van Buuren HR, Ponsioen CY, Trivedi PJ, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Verhelst X, Janssen HLA, Hansen BE; Gulamhusein A, GLOBAL PBC Study Group
Aliment. Pharmacol. Ther. 2019;50(10):1127-1136
57. Number Needed to Treat with Ursodeoxycholic Acid Therapy to Prevent Liver Transplantation or Death in Primary Biliary Cholangitis
Harms M., Deever R, Lammers WJ, Corpechot C, Thorburn D, Janssen H, Lindor K, Trivedi PJ, Hirschfield G, Pares A, Floreani A, Mayo M, Battezzati PM, Nevens F, Ponsioen CY, Mason A, Kowdley, Hansen BE, van Buuren H, van der Meer A, GLOBAL PBC Study Group
Gut 2019; 69(8):1502-1509
58. Chronic Kidney Disease After Liver Transplantation: Impact of Extended Criteria Grafts.
Kalisvaart M, Schlegel A, Trivedi PJ, Roberts K, Mirza DF, Perera T, Isaac JI, Ferguson J, de Jonge J, Muiesan P.
Liver Transplantation 2019;25(6):922-933
59. Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis.
Lemoine S, Cazzagon N, El Mouhadi S, Trivedi PJ, Dohan A, Kemgang A, Ben Belkacem K, Housset C, Chretien Y, Corpechot C, Hirschfield G, Floreani A, Motta R, Gallix B, Barkun A, Barkun J, Chazouillères O, Arrivé L.
Clin Gastroenterol Hepatol. 2019 [Epub, Ahead of print]



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology



April 16-17, 2022 Virtual Congress

60. Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation
Steenstraten I.C., Sebib Korkmaz K., Trivedi P.J., Inderson A, van Hoek B, Rodriguez Gironde M.D.M., Maljaars P.W.J.
Aliment. Pharmacol. Ther. 2019;49(6):636-643.
61. Effects of Age and Sex of on Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.
Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi P.J., Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HL, Hansen BE; Global PBC Study Group.
Clin Gastroenterol Hepatol. 2019;17(10):2076-2084.e2
62. Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival.
Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi PJ, Hirschfield G, McDowell P, Poupon R, Dumortier J, Bosch A, Giotria E, Conti F, Parés A, Reig A, Floreani A, Russo FP, Goet J, Harms MH, van Buuren H, Van den Ende N, Nevens F, Verhelst X, Donato MF, Malinverno F, Ebadi M, Mason AL; Global PBC Study Group.
Gastroenterology 2019;156(1):96-107.e1
63. Challenges in the use of corticosteroids in the management of autoimmune hepatitis.
Chapman RW, Aspinall RJ, Trivedi P, Wright G, Heneghan M.
Br. J. Hosp. Med. 2019;80(10):594-599
64. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.
Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.
Hepatology. 2018 May;67(5):1920-1930
65. Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.
Goode EC, Clark AB, Mells GM, Srivastava B, Spiess K, Gelson WTH, Trivedi PJ, Lynch KD, Castren E, Vesterhus MN, Karlsen TH, Ji SG, Anderson CA, Thorburn D, Hudson M, M H, Aldersley MA, Bathgate A, Sandford RN, Alexander GJ, Chapman RW, Walmsley M; UK-PSC Consortium, Hirschfield GM, Rushbrook SM.
Hepatology 2019;69(5):2120-2135
66. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history
Perez FM, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A.,



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology



April 16-17, 2022 Virtual Congress

- Nevens F., Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen H. and Hansen B.E.
Hepatology 2018;67(5):1920-1930
67. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrupf E, Nevens F, Trivedi PJ, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group
Journal of Hepatology 2017;67(3):549-558
68. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study
de Vries EM, de Krijger M, Färkkilä M, Arola J, Schirmacher P, Gotthardt D, Goepfert B, Trivedi PJ, Hirschfield GM, Ytting H, Vainer B, Buuren HR, Biermann K, Harms MH, Chazouilleres O, Wendum D, Kemgang AD, Chapman RW, Wang LM, Williamson KD, Gouw AS, Paradis V, Sempoux C, Beuers U, Hübscher SG, Verheij J and Ponsioen CY
Hepatology 2017; 65(3):907-919
69. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD
Quraishi MN, Sergeant M, Kay G, Iqbal T, Chan J, Constantinidou C, Trivedi PJ, Ferguson J, Adams DH, Pallen M and Hirschfield GM
Gut 2016; 66(2):386-388
70. Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how?
Li KK, Trivedi PJ, Von Heimendahl S, Bruns T, Ward ST, Oo Y and Mutimer D
Hepatology 2016; 63(4):1394-5
71. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy
Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Burroughs AK, Mason AL, Kowdley KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A, Lleo A, Caballeria L, Hansen BE and van Buuren HR; Global PBC Study Group
Gastroenterology 2016; 149(7):1804-1812e4
72. Letter: serum vitamin D levels in primary biliary cirrhosis
Bruns T, Kittler C, Stengel S, Trivedi PJ, Stallmach A
Alimentary Pharmacology and Therapeutics 2015; 42(5):633-4
73. CMV infection of human sinusoidal endothelium regulates hepatic T cell recruitment and activation
Bruns T, Zimmermann HW, Pachnio A, Li KK, Trivedi PJ, Reynolds G, Hübscher S, Stamataki Z, Badenhorst PW, Weston CJ, Moss PA and Adams DH
Journal of Hepatology 2015; 63(1):38-49
74. Elevation of the JVP in constrictive pericarditis
Sutherland RK, Russell KV, Trivedi PJ, Conlon CP and Smith RW
Quarterly Journal of Medicine 2015; 108(10):846



SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



75. Alkaline phosphatase and bilirubin values are surrogates of outcome for patients with primary biliary cirrhosis – an international, multi-centre, meta-analysis
Lammers WJ van Buuren HR, Hirschfield GM, Janssen HLA, Invernizzi P, Mason AL, Talwalkar J, Ponsioen CY, Floreani A, Corpechot C, Mayo M, Battezzati PM, Pares A, Nevens F, Burroughs AK, Kowdley K, Trivedi PJ, Kumagi T, Cheung A, Lleo A, Imam M, Boonstra K, Cazzagon N, Franceschet I, Poupon R, Caballeria L, Pieri G, Kanwar P, Lindor K and Hansen BE
Gastroenterology 2014; 147(6):1338-49
76. Loss of CD28 Expression by Liver-infiltrating T cells Contributes to Pathogenesis of Primary Sclerosing Cholangitis
Liaskou E, Jeffery LE, Trivedi PJ, Reynolds GM, Suresh S, Bruns T, Adams DH, Sansom DM and Hirschfield GM
Gastroenterology 2014; 147(1): 221-232
77. A Constricting Differential – A Case of Severe Anaemia, Weight Loss and Pericarditis Due to Tropheryma Whipplei Infection
Sutherland RK, Russell KV, Trivedi PJ, Warren B, Smith RW, Conlon CP
QJM 2014; 107(11):927-9
78. Relaxin Modulates Human and Rat Hepatic Myofibroblast Function and Ameliorates Portal Hypertension In Vivo
Fallowfield J, Hayden A, Snowdon V, Aucott R, Stutchfield B, Mole D, Pellicoro A, Gordon-Walker T, Henke A, Schrader J, Trivedi P, Princivalle M, Forbes S, Collins J and Iredale J
Hepatology 2013; 59(4):1492-504
79. First presentation ulcerative colitis patients seen in the colorectal surgery clinic receive earlier medical treatment compared to those in medical gastroenterology
Ward S, Li K, Trivedi PJ, Hejmadi RK, Suggett N, Iqbal T and Ismail T
Colorectal Disease 2013; 15(7):836-41
80. Intraductal Papillary Mucinous Neoplasm in Chronic Calcifying Pancreatitis: Egg or Hen?
Kalaitzakis E, Braden B, Trivedi P, Sharifi Y and Chapman R
World Journal of Gastroenterology 2009; 15 (10):1273-5